The impact of compliance with osteoporosis therapy on fracture rates in actual practice

Abstract

These results indicate that improving compliance in actual practice may significantly decrease osteoporosis-related fracture risk.

Long-term impact of adherence to oral bisphosphonates on osteoporotic fracture incidence

“…The low adherence levels observed in our study are consistent with rates found in other studies in the literature with shorter follow-up and smaller number patients; Briesacher and colleagues reported a compliance rate of 42% over 1 year of treatment with bisphosphonates, (34) whereas in a different study they reported an MPR 80% of 42.9%, 34.5%, and 30.6% after 1, 2, and 3 years, respectively. (35) Caro and colleagues (30) reported an MPR 80% of 49.4% over a 2-year follow-up; Curtis and colleagues (36) reported 44%, 39%, and 36% at 1, 2, and 3 years, respectively; Penning van Beest and colleagues (37) reported 66%, 58%, 49%, and 40% at 6 months, 1 year, 2 years, and 3 years, respectively; and Siris and colleagues (32) reported 43% over a 2-year follow-up. With regard to persistence, Melo and Table 3.…”

“…Strong evidence in the literature indicates that adherence to osteoporosis medication is associated with a reduced risk of fractures. (25,30,31) Siris and colleagues reported a linear association between adherence to osteoporosis medications and incidence of fractures during a 2-year treatment period, (32) whereas Curtis and colleagues showed a similar linear effect by evaluating adherence in a time-varying manner over 2.5 years. (33) To date, the studies measuring adherence to OBP treatment and its association with fracture risk have been conducted over short treatment durations, specifically 1 to 3 years.…”

Differences in persistence, safety and efficacy of generic and original branded once weekly bisphosphonates in patients with postmenopausal osteoporosis: 1-year results of a retrospective patient chart review analysis

“…The effectiveness of a treatment however, depends not only on the efficacy of the used medication but also on persistent drug intake of patients [25][26][27][28]. Drugs do not work in patients who do not take them.…”

“…Different studies in recent years proved significant correlations between compliance and therapeutic results during bisphosphonate therapy [26,34,35]. It was shown that noncompliance with antiresorptive therapies has been associated with a 16-50% increased risk of fracture [26,[34][35][36][37][38].…”

“…Also it was proven that subgroups with good compliance with bisphosphonates (e.g. over 80%) had higher increases in bone mineral density (BMD) and a significantly stronger effect on fracture risk than those with poor compliance [26,27,37].…”